Top

Published in:

Open Access 01-12-2016 | Short Communication

Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus

Authors: Milton H. Werner, DeRen Huang

Published in: Journal of NeuroVirology | Issue 6/2016

Abstract

Sixty-three natalizumab-treated patients with relapsing multiple sclerosis were screened for JC polyomavirus (JCV) viruria. Urinary-positive patients were longitudinally sampled for up to 24 weeks. Using methods that distinguish encapsidated virus from naked viral DNA, 17.5 % of patients were found to excrete virus, consistent with the prevalence of urinary excretion in the general population. Unexpectedly, urinary excretion was predominantly seen (>73 %) in patients with high JC antibody index (≥2.0). Active JCV infection, therefore, tends to occur in natalizumab patients that carry a high risk factor for the development of disease, directly linking JC infection to the risk factors for PML development.

Bellizzi A, Anzivino E, Rodio DM, Cioccolo S, Scrivo R, Morreale M, Pontecorvo S, Ferrari F, Di Nardo G, Nencioni L, Carluccio S, Valesini G, Francia A, Cucchiara S, Palamara AT, Pietropaolo V (2013) Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study. Virol J 10:298CrossRefPubMedPubMedCentral

Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ (2013) JC virus antibody status underestimates infection rates. Ann Neurol 74:84–90CrossRefPubMedPubMedCentral

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870–1880CrossRefPubMed

Clausi V, Giannecchini S, Magnani E, Repice A, Mechi C, Martelli F, Azzi A, Massacesi L (2015) Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. Neurol Neuroimmunol Neuroinflamm 2:e58CrossRefPubMedPubMedCentral

Delbue S, Elia F, Carloni C, Pecchenini V, Franciotta D, Gastaldi M, Colombo E, Signorini L, Carluccio S, Bellizzi A, Bergamaschi R, Ferrante P (2015) JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients. J Neurovirol 21:645–652CrossRefPubMed

Domínguez-Mozo MI, Garcia-Montojo M, De Las HV, Garcia-Martinez A, Arias-Leal AM, Casanova I, Arroyo R, Alvarez-Lafuente R (2013) Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish multiple sclerosis patients treated with natalizumab. J Neuroimmune Pharmacol 8:1277–1286CrossRefPubMed

Domínguez-Mozo MI, García-Montojo M, Arias-Leal A, García-Martínez Á, Santiago JL, Casanova I, Galán V, Arroyo R, Fernández-Arquero M, Alvarez-Lafuente R (2015) Monitoring John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. Eur J Neurol. doi:10.1111/ene.12834 PubMed

Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P (2011) Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 204:103–114CrossRefPubMedPubMedCentral

Lanzillo R, Liuzzi R, Vallefuoco L, Vallefuoco L, Moccia M, Amato L, Vacca G, Vacchiano V, Portella G, Brescia MV (2014) JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. Ther Clin Risk Manag 10:807–814PubMedPubMedCentral

Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE (2012) Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol 7:665–672CrossRefPubMed

McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2015) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2015-311100, Online first October 22, 2015

Neu U, Maginnis MS, Palma AS, Ströh LJ, Nelson CD, Feizi T, Atwood WJ, Stehle T (2010) Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe 8:309–319CrossRefPubMedPubMedCentral

Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802–812CrossRefPubMed

Reid CE, Li H, Sur G, Carmillo P, Bushnell S, Tizard R, McAuliffe M, Tonkin C, Simon K, Goelz S, Cinque P, Gorelik L, Carulli JP (2011) Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 204:237–244CrossRefPubMedPubMedCentral

Rinaldi L, Rinaldi F, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Palú G, Gallo P (2010) No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study. J Neurol Neurosurg Psychiatry 81:1345–1350CrossRefPubMed

Rudick RA, O’Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, E Goelz S (2010) Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 68:304–310CrossRefPubMed

Ryschkewitsch C, Jensen P, Hou J, Fahle G, Fischer S, Major EO (2004) Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 121:217–221CrossRefPubMed

Saundh BK, Tibble S, Baker R, Sasnauskas K, Harris M, Hale A (2010) Different patterns of BK and JC polyomavirus reactivation following renal transplantation. J Clin Pathol 63:714–718CrossRefPubMed

Van Loy T, Thys K, Tritsmans L, Stuyver LJ (2013) Quasispecies analysis of JC virus DNA present in urine of healthy subjects. PLoS One 8, e70950CrossRefPubMedPubMedCentral

Van Loy T, Thys K, Ryschkewitsch C, Lagatie O, Monaco MC, Major EO, Tritsmans L, Stuyver LJ (2015) JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route. J Virol 89:1340–1347CrossRefPubMed

Wollebo HS, White MK, Gordon J, Berger JR, Khalili K (2015) Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 77:560–570CrossRefPubMedPubMedCentral

Title: Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
Authors: Milton H. Werner
DeRen Huang
Publication date: 01-12-2016
Publisher: Springer International Publishing
Published in: Journal of NeuroVirology / Issue 6/2016
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-016-0449-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Elevated stress is associated with prefrontal cortex dysfunction during a verbal memory task in women with HIV

Normonatremic osmotic demyelination in the setting of acquired immune deficiency syndrome and malnutrition: case report and literature review

Exosome-associated release, uptake, and neurotoxicity of HIV-1 Tat protein

Utility of a brief computerized battery to assess HIV-associated neurocognitive impairment in a resource-limited setting

Acute myelitis as presenting symptom of HIV-HTLV-1 co-infection

Adenovirus-mediated shRNA interference against HSV-1 replication in vitro